Stock Track | Sarepta Therapeutics Soars 5% After Announcing Scholarship Program and Upbeat Earnings

Stock Track
02-28

Sarepta Therapeutics (SRPT) stock surged 5.13% in pre-market trading on Friday, following the company's announcement of its annual scholarship program for individuals living with Duchenne muscular dystrophy and their siblings, as well as the release of its impressive full-year 2024 earnings results.

The biotech company, known for its precision genetic medicine for rare diseases, unveiled the 8th annual Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program offers academic scholarships of up to $5,000 to as many as 20 individuals with Duchenne and five siblings. This initiative highlights Sarepta's commitment to supporting the Duchenne community and their educational aspirations.

Additionally, Sarepta reported strong financial performance for the full year 2024. The company's revenue surged 53% year-over-year to $1.90 billion, exceeding analyst expectations. While earnings per share fell short of estimates, Sarepta achieved net income of $235.2 million, marking a significant improvement from the previous year's net loss of $536 million. The company's robust revenue growth and transition to profitability contributed to the stock's upward momentum.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10